Table 6.
TJA and mean dosage of glucosamine sulfate (GS) among four GS utilization patterns.
| Group | χ2/F | p-Value * | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Constant Use, Still Continued NSAID Use (n = 47) |
Constant Use, Reduced NSAID Use (n = 19) |
Finally Abandoned Use, Returned Back to NSAID Use Only (n = 189) |
Irregular Pattern (n = 16) |
|||||||
| n | (%) | n | (%) | n | (%) | n | (%) | |||
| TJA | 5.297 | 0.151 | ||||||||
| Yes | 2 | (4.3) | 0 | (0.0) | 15 | (7.9) | 3 | (18.8) | ||
| No | 45 | (95.7) | 19 | (100.0) | 174 | (92.1) | 13 | (81.3) | ||
| Mean GS daily dosage (mg) † | 697 ± 197 ‡ | 726 ± 263 | 669 ± 218 | 669 ± 345 | 0.493 | 0.688 | ||||
† The mean GS total daily dose was counted during the period of usage. ‡ Mean ± SD: the mean with the standard deviation. * No significant difference was noted in the p-value among the four different GS utilization patterns. TJA, total joint arthroplasty; NSAID, nonsteroidal anti-inflammatory drug.